Is Syngene International (SYNGENE) overvalued or fairly valued?

MarketChacha shows Syngene International's valuation in context — a forward P/E of about 33.3, a price-to-book of about 3.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Syngene International's revenue?

Syngene International reported revenue of ₹3,739 Cr for FY2026, with net profit of ₹317 Cr, per official filings.

What is the share price of Syngene International (SYNGENE)?

Syngene International last traded at ₹412.75 (-1.1% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Syngene International

SYNGENE · NSE · Pharma/CRO · India

₹412.75-1.1%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:38 AM

Snapshot

TickerSYNGENE

ExchangeNSE

SectorPharma/CRO

IndustryDiagnostics & Research

CountryIndia

Employees6,692

HeadquartersBengaluru, India

Market cap₹16,778 Cr

P/B3.5

Volume1.64L

Websitewww.syngeneintl.com

Filings tracked0

About Syngene International

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Profile as reported by Yahoo Finance.

Who owns it

Promoters52.8%
Institutions38.2%
Public & other9.0%

81 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 6.1 points over the period — profitability is trending down.

Net margin trend14.5% → 8.5%

Margin has compressed by about 6.1 points over the period — profitability is trending down.

Growth qualityrev 5% · PAT -12%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹865 Cr · EPS 1.63

Est. earnings growth -2.4%

Next fiscal year

Rev ₹4,513 Cr · EPS 12.54

Est. earnings growth +37.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹380.0052-wk range₹728.60

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹16,778 Cr

Day change

-1.1%

Fwd P/E

33.3

P/B

3.5

Div yield

0.30%

Beta

-0.00

Revenue (FY2026)

₹3,739 Cr

Net margin

8.5%

Revenue CAGR (3y)

+5.4%

Profit CAGR (3y)

-12.0%

Net profit (FY2026)

₹317 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about SYNGENE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹3,739 Cr	₹317 Cr	8.5%
FY2025	₹3,642 Cr	₹496 Cr	13.6%
FY2024	₹3,489 Cr	₹510 Cr	14.6%
FY2023	₹3,193 Cr	₹464 Cr	14.5%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹1,037 Cr	₹148 Cr	14.3%
2025Q4	₹917 Cr	₹15 Cr	1.6%
2025Q3	₹911 Cr	₹67 Cr	7.4%
2025Q2	₹875 Cr	₹87 Cr	9.9%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.